ArticleTherapeutic advances in medical oncology2021

Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study.

Raymond S McDermott et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.